Bristol-Myers Squibb Recalls Opdualag Injection Over Sterility Issue
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Product Details
Opdualag injection (Nivolumab and Relatlimab-rmbw) comes in 240 mg and 80 mg/20 mL single-dose vials. The recalled lot number is 033A23B, with an expiration date of April 30, 2026.
The Hazard
The recall is due to a lack of assurance of sterility, which poses a high risk of infection. Sterility is critical for injectable medications.
What to Do
Stop using the Opdualag injection immediately. Contact Bristol-Myers Squibb or your healthcare provider for further guidance.
Contact Information
For assistance, call Bristol-Myers Squibb at 1-800-XXX-XXXX or visit their website for more information.